STUDY TITLE
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.
STUDY DESIGN
Multicentre, open label, prospective, single arm study
CORRELATIVE STUDIES
Blood and bone marrow samples are collected for assessment of minimal residual disease (MRd) and for purification and storage for potential future exploratory biomarker studies
TRIAL PRINCIPAL INVESTIGATOR
Professor Andrew Spencer
TIME FRAME
2016 – 2018
PARTICIPANTS
Patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy
TOTAL ENROLMENT
40
STATUS
Closed to recruitment
SITE LOCATIONS
-
Alfred Hospital, VIC